Physician profile
Gerald Cioce
NPI 1093817512
$7,441.07
in general payments reported to CMS, 2019-2025
34 companies · $974 in 2025
The $974 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,975 · 2020: $453 · 2021: $486 · 2022: $1,166 · 2023: $1,109 · 2024: $1,278 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239 · Entertainment: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,238.62 |
| Entertainment | $122.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $1,742.45 | 2019-2023 | |
| Abbott Laboratories | $1,294.57 | 2019-2025 | Diamondback Coronary, Xience Skypoint, Diamondback Peripheral |
| Medtronic, INC. | $857.38 | 2021-2025 | Ffrangio, Symplicity G3, Onyx Frontier |
| Abiomed | $471.29 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $332.45 | 2019-2024 | |
| Shockwave Medical, INC | $323.44 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave S4 |
| Janssen Pharmaceuticals, INC | $314.64 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $297.48 | 2019-2025 | Lifevest |
| Opsens INC. | $296.53 | 2022-2023 | Optowire |
| Boston Scientific Corporation | $249.54 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Amgen INC. | $173.14 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $165.03 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $164.76 | 2019-2025 | |
| Novo Nordisk INC | $82.59 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $78.81 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $76.05 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $67.63 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.45 | 2019 | |
| Penumbra, INC. | $45.74 | 2022-2023 | Indigo System |
| Merck Sharp & Dohme LLC | $44.19 | 2023-2024 | Verquvo, Zerbaxa, Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $40.69 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $40.46 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $32.33 | 2024 | Arcalyst |
| Cleerly, INC. | $29.80 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Lantheus Medical Imaging, INC. | $22.61 | 2023 | Definity |
| Bridgebio Pharma, INC. | $19.00 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $18.96 | 2025 | Onpattro |
| Cordis US Corp. | $16.14 | 2022 | |
| Esperion Therapeutics, INC. | $15.93 | 2025 | Nexletol |
| Bard Peripheral Vascular, INC. | $15.67 | 2021 | |
| Amarin Pharma, INC. | $15.03 | 2023 | |
| Ionis Pharmaceuticals, INC. | $14.88 | 2025 | Tryngolza |
| Kiniksa Pharmaceuticals, LTD. | $14.10 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Cioce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.